<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01728727</url>
  </required_header>
  <id_info>
    <org_study_id>20120912-3</org_study_id>
    <nct_id>NCT01728727</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis</brief_title>
  <official_title>Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HBV related Liver disease is a common medical problem in China. An estimated 7.18% of the
      Chinese (about 93 million) is infected with hepatitis B, and most of the HBV- related
      hepatitis can developed into liver cirrhosis.

      Liver transplantation is the only available life saving treatment for patients with end stage
      liver disease. However, lack of donors, surgical complications, rejection, and high cost are
      serious problems.

      Mesenchymal stem cells (MSCs) possess plasticity and have the potential to differentiate into
      hepatocyte; Thus, MSCs hold great hope for therapeutic applications. Human umbilical
      cord-derived MSCs (hUC-MSCs) exhibit a more beneficial immunogenic profile and greater
      overall immunosuppressive potential than aged bone marrow-derived MSCs. Like MSCs derived
      from bone marrow, hUC-MSCs can also be used to treat rat liver fibrosis and improve glucose
      homeostasis in rats with liver cirrhosis. In this study, the patients with HBV-related liver
      cirrhosis will undergo administration of hUC-MSCs via hepatic artery to evaluate the safety
      and efficacy of hUC-MSC treatment for these patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>one year survival rate</measure>
    <time_frame>one year after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MELD score</measure>
    <time_frame>1week, 4weeks,3months, 6months, 9months and 1year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Pugh Score</measure>
    <time_frame>1week, 4weeks,3months, 6months, 9months and 1year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alpha fetoprotein</measure>
    <time_frame>1week, 4weeks,3months, 6months, 9months and 1year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>1week, 4weeks,3months, 6months, 9months and 1year after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>End Stage Liver Disease</condition>
  <arm_group>
    <arm_group_label>conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional treatment &amp; antiviral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UC-MSC transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>UC-MSC transplantation</intervention_name>
    <description>After enrolled, Participant will receive umbilical cord MSC transplantation of 1*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit</description>
    <arm_group_label>UC-MSC transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional treatment</intervention_name>
    <description>Participants will receive conventional treatment and antiviral treatment.</description>
    <arm_group_label>conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-65 years

          2. HBV-related liver cirrhosis

          3. Child-Pugh score 9-15

          4. Written consent -

        Exclusion Criteria:

          1. Hepatocellular carcinoma or other malignancies

          2. Severe problems in other vital organs(e.g.the heart,renal or lungs)

          3. Pregnant or lactating women

          4. Severe bacteria infection

          5. Anticipated with difficulty of follow-up observation

          6. Other candidates who are judged to be not applicable to this study by doctors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiming Fan</last_name>
    <role>Study Chair</role>
    <affiliation>Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ying han</last_name>
    <phone>86-29-84771539</phone>
    <email>hanying@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yongquan shi</last_name>
    <phone>86-29-84771515</phone>
    <email>shiyquan@fmmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Han</last_name>
      <phone>86-29-84771539</phone>
      <email>hanying@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yongquan Shi</last_name>
      <phone>86-29-84771515</phone>
      <email>shiyquan@fmmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>November 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2012</study_first_posted>
  <last_update_submitted>November 13, 2012</last_update_submitted>
  <last_update_submitted_qc>November 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Han Ying</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>end stage liver disease</keyword>
  <keyword>umbilical cord</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

